10/527686

1 1 MAR 2005 DT09 Rec'd R



Appl. No.

: National Phase Entry PCT/CA2003/001343

Applicant

: Lorne J. BRANDES

Filed

: March 11, 2005

TC/A.U.

Examiner

Docket No.

: 3172-106

Customer No.: 6449

Confirmation No. :

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with applicants duty of disclosure under 37 C.F.R. 1.56, enclosed is a copy of the International Search Report in the corresponding international application. The relevance of the references is noted in the International Search Report. We understand that the references have been forwarded by the International Bureau, and are available to the Examiner, but if the Examiner needs copies of any of the references, the Examiner is requested to advise counsel accordingly.

In the event that any fees are due with this paper, please charge our Deposit Account No. 02-2135.

Respectfully submitted,

Robert B. Murray

Attorney for Applicant

Registration No. 22,980

ROTHWELL, FIGG, ERNST & MANBECK

1425 K. Street, Suite 800 Washington, D.C. 20005

Telephone: (202) 783-6040

RBM/cb

					Complet		
				Application Number	New Application 7686		
	INFORMATION DISCLOSURE				Herewith		
STATEMENT BY APPLICANT			NT	First Named Inventor	Lorne J. Brandes		
				Examiner Name			
				Confirmation No.			
Sheet	1	of	3	Attorney Docket Number	3172-106		

			U.S. F	PATE	ENT DOCUMENTS	
Examiner Cite Initials* No.1		U.S. Patent D	ocument		Name of Patentee or Applicant of Cited Document	Date of Publication
	Number Kind (		de²	of Cited Document	of Cited Document MM-DD-YYYY	
	1.	5,618,846		Α	Lorne Brandes	4/8/97
	1					
		1				
· 16*						
· · · · · · · · · · · · · · · · · · ·	ļ					
	<u> </u>					
				_		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

## DT09 Rec'd PCT/PTO 1 1 MAR 2005

			•	Complet		
				Application Number	New Application	
	TION DISC			Filing Date	Herewith 52/686	
STATEMENT BY APPLICANT			NT	First Named Inventor Lorne J. Brandes		
				Group Art Unit		
				Examiner Name		
				Confirmation No.		
Sheet	2	of	3	Attorney Docket Number	3172-106	

			FOR	EIGN PATE	ENT DOCUMEN	TS	
Examiner Initials*	Cite No.1	Office <sup>3</sup> Code	oreign Patent Docur Number⁴	ment Kind <sup>5</sup> (if known)	Name of Paten Cited I	itee or Applican Document	Date of Publication of Cited Document MM-DD-YYYY
	2.	wo	03 039526	А	Univ Manitoba		5/15/03
	3.	wo	03 037318	А	Mark Vincent		5/8/03
						<del></del> -	
		<u> </u>					
		-					
		<u> </u>					
		<del></del>			· · · · · · · · · · · · · · · · · · ·		
		<u>.                                      </u>					
	<u> </u>	_	L				
Examiner Signature						Date Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

				1 THAT EVOC				
				Completent				
				Application Number	New Application			
INFORMATION DISCLOSURE		Filing Date	Heredin 527686					
STATEMENT BY APPLICANT			NT	First Named Inventor Lorne J. Brandes				
				Group Art Unit				
				Examiner Name				
				Confirmation No.				
Sheet	3	of	3	Attorney Docket Number	3172-106			

		NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published						
	4.	Brandes et al., "Results of a human pilot study testing the hypothesis that the intracellular histamine antagonist DPPE increases the therapeutic index of doxorubicin; ADVANCES IN THE BIOSCIENCES", 1993, pgs. 375-401.						
	5.	Anonymous: "Annual information form" INTERNET ARTICLE, "Online", 30 June 2001, pgs. 1-18.						
	6. Brandes et al., "High complete and overall response rates of metastatic breast cancer to diethyl", BREAST CANCER RESEARCH AND TREATMENT, vol. 46, no. 1, October 1 pg. 60, December 3-6, 1997.							
	7.	Khoo et al., "Phase II Trial of N,N-Diethyl-2-Ä4-(Phenylmethyl)Phenoxyüeth Anamine", A NATIONAL CANCER INSTITUTE OF CANADA CLINICAL TRIALS GROUP STUDY, "JOURNAL OF CLINICAL ONCOLOGY, vol. 17, no. 11, November 1999, pgs. 3431-3437.						
	8.	Brandes et al.,, N,N-Diethyl-2-'4-(Phenylmethyl)-Phenoxy!, "THE INTRACELLUAR HISTAMINE ANTAGONIST", vol. 49, no. 1, May 1998, pgs. 61-68.						
· · · · · · · · · · · · · · · · · · ·								
Examiner Signature		Date Considered						

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.